Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

NCT03508700 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03508700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03508700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Lead sponsor
Tonix Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 19, 2018
Completion date
September 30, 2019
Enrollment
93 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd